Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024.

Virchows Archiv : an international journal of pathology·2026
Same author

A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

Cancers·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Blood·2026
Same author

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Haematologica·2026
Same author

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: May 26, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

MALT lymphomas: pathogenesis can drive treatment.

Francesco Bertoni1, Bertrand Coiffier, Gilles Salles

  • 1Lymphoma Unit and Institute of Oncology Research, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.

Oncology (Williston Park, N.Y.)
|January 11, 2012
PubMed
Summary

Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma. Gastric MALT lymphoma treatment eradicating Helicobacter pylori infection is effective, while non-gastric MALT lymphoma treatments are less established.

More Related Videos

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis
07:45

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Published on: January 26, 2024

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Experiment Videos

Last Updated: May 26, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis
07:45

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Published on: January 26, 2024

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Area of Science:

  • Oncology
  • Hematology
  • Immunology

Background:

  • Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma is an indolent B-cell non-Hodgkin lymphoma.
  • Genetic abnormalities activating the nuclear factor kappa B (NF-kappaB) pathway characterize these lymphomas.
  • While the stomach is the most common site, MALT lymphomas can arise in any extranodal organ.

Purpose of the Study:

  • To review the current understanding of MALT lymphoma development and treatment.
  • To highlight the link between Helicobacter pylori infection and gastric MALT lymphoma.
  • To discuss treatment strategies for both gastric and non-gastric MALT lymphomas.

Main Methods:

  • Literature review of MALT lymphoma.
  • Analysis of genetic abnormalities and their role in pathogenesis.
  • Evaluation of treatment outcomes for gastric and non-gastric MALT lymphomas.

Main Results:

  • H. pylori eradication is a highly effective treatment for gastric MALT lymphoma.
  • Non-gastric MALT lymphomas have weaker associations with microorganisms.
  • Established treatments for non-gastric MALT lymphomas include radiotherapy and systemic therapy (chemotherapy/rituximab).

Conclusions:

  • Gastric MALT lymphoma treatment targeting H. pylori serves as a model for causative factor eradication.
  • Treatment for non-gastric MALT lymphomas is less established and requires further investigation.
  • Antibiotic therapy for non-gastric MALT lymphomas remains investigational.